Sven Mahner, MD, PhD of the University Medical Center Hamburg-Eppendorf Hamburg, Germany talks about the Phase III trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial, NCT01847274). Dr Mahner explains that ovarian cancer is a common disease, which in the first-line setting, needs extensive surgery and chemotherapy. However, the majority of patients recur and they are re-treated with chemotherapy. The trial looked at maintenance therapy with niraparib after recurrent chemotherapy. According to Dr Mahner, they observed a large benefit for patients receiving niraparib maintenance in both, the germline BRCA (gBRCA) mutation and non-gBRCA mutated patient populations.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
